EGFR and lung cancer: The treatment with IFNγ up-regulated the surface expression of MHC-I, MHC-II, and PD-L1 more frequently on lung cancer cell lines sensitive to erlotinib than on those resistant erlotinib (Figs 2C, 3C and 4C), suggesting that EGFR-driven lung cancer may be immunologically reactive.